

**REMARKS**

The claims set forth above find support throughout the application as originally filed, as well as support in each priority application, beginning with the Applicants' 1992 application, U.S.S.N. 07/959,951. Much of the claim language is similar to claim language in U.S. Patent No. 5,776,755, which issued from the 1994 priority application. Claims to the related polypeptide and polynucleotide subject matters were examined together in the parent '755 patent and found allowable. The applicants request continued joinder of such claims in the present case, and believe that no serious burden would be involved in such examination.

Referring to the earliest priority application, support for claims to fragments of the Flt4 receptor (or polynucleotides that encode them) is found, e.g., in the summary of invention on pages 3-5, including the paragraph bridging pages 4-5; in the detailed description at pages 9-10; and in a paragraph pertaining to derivatives, analogs, and peptides at page 15.

Identification of the extracellular domain of Flt4 is found in Figure 2 and, e.g., at pages 18-19 of the priority application. Likewise, a comparison to Flt1, the closest known homolog at the time, is provided in the figure and at these pages.

Antibody production using Flt4 peptides and use thereof are described, e.g., at pages 15-18 of the priority application.

The Applicants invite the examiner to contact the undersigned attorney if questions arise during examination, or if the examiner has suggestions for expediting allowance.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN LLP  
6300 Sears Tower  
233 South Wacker Drive  
Chicago, Illinois 60606-6402  
(312) 474-6300

By:



David A. Gass  
Registration No. 38,153  
Attorney for Applicants

December 10, 2003